References:
1. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref.
[Last accessed: March 2023].
2. Góralska K et al. Infection. 2018;46(4):443–459.
3. Stott KE et al. Lancet Infect Dis. 2021;21(9):e259–e271.
4. Hamill RJ et al. Clin Infect Dis. 2010;51(2):225–232.
5. Wheat J et al. Medicine (Baltimore). 2018;97(13):e0245.
6. Wheat LG et al. Antimicrob Agents Chemother. 2001;45(8):2354–2357.
7. Johnson PC et al. Ann Intern Med. 2002;137(2):105–109.
8. Walsh TJ et al. N Engl J Med. 1999;340(10):764–771.
9. Falci DR et al. Mycoses. 2015;58(2):104–112.
10. Adler-Moore JP and Proffitt RT. J Antimicrob Chemother. 2002;
49(Suppl. 1):21–30.
11. Keady S and Panesar P. EJHP Practice. 2010;16(3):78–80.
12. Stone NR et al. Drugs. 2016;76(4):485–500.
13. Adler-Moore JP et al. Med Mycol. 2016;54(3):223–231.
14. Ullmann A et al. Clin Infect Dis. 2006;43(4):e29–e38.
15. Wingard JT et al. Clin Infect Dis. 2000;31(5):1155–1163.
16. Adler-Moore JP et al. Curr Opin Investig Drugs. 2003;4(2):179–185.
17. Walker L et al. MBio. 2018;9(1):e02383–17.
18. Hevey MA et al. J Acquir Immune Defic Syndr. 2019;82(1):81–87.
19. Srichatrapimuk S and Sungkanuparph S. AIDS Res Ther. 2016;13(1):42.
20. World Health Organization. Guidelines for the diagnosis, prevention and
management of cryptococcal disease in HIV-infected adults, adolescents and
children. Available at: https://www.who.int/publications/i/item/9789241550277
[Last accessed: March 2023].
References:
1. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref. [Last accessed: March 2023].
14. Ullmann A et al. Clin Infect Dis. 2006;43(4):e29–e38.
15. Wingard JT et al. Clin Infect Dis. 2000;31(5):1155–1163.
16. Adler-Moore JP et al. Curr Opin Investig Drugs. 2003;4(2):179–185.
17. Walker L et al. MBio. 2018;9(1):e02383–17.
18. Hevey MA et al. J Acquir Immune Defic Syndr. 2019;82(1):81–87.
19. Srichatrapimuk S and Sungkanuparph S. AIDS Res Ther. 2016;13(1):42.
20. World Health Organization. Guidelines for the diagnosis, prevention and management
of cryptococcal disease in HIV-infected adults, adolescents and children. Available at:
https://www.who.int/publications/i/item/9789241550277 [Last accessed: March 2023].
2. Góralska K et al. Infection. 2018;46(4):443–459.
3. Stott KE et al. Lancet Infect Dis. 2021;21(9):e259–e271.
4. Hamill RJ et al. Clin Infect Dis. 2010;51(2):225–232.
5. Wheat J et al. Medicine (Baltimore). 2018;97(13):e0245.
6. Wheat LG et al. Antimicrob Agents Chemother. 2001;45(8):2354–2357.
7. Johnson PC et al. Ann Intern Med. 2002;137(2):105–109.
8. Walsh TJ et al. N Engl J Med. 1999;340(10):764–771.
9. Falci DR et al. Mycoses. 2015;58(2):104–112.
10. Adler-Moore JP and Proffitt RT. J Antimicrob Chemother. 2002;49(Suppl. 1):21–30.
11. Keady S and Panesar P. EJHP Practice. 2010;16(3):78–80.
12. Stone NR et al. Drugs. 2016;76(4):485–500.
13. Adler-Moore JP et al. Med Mycol. 2016;54(3):223–231.
This educational tool is developed and fully funded by Gilead Sciences, and it is intended for healthcare
professionals only. It contains information about Gilead products, educational materials on therapy areas,
and professional resources.
Prescribing information for Liposomal Amphotericin B